

**I. Amendments To Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-24. (Cancelled)

Claim 25. (Original) A therapeutic method comprising providing to a patient in need of tranexamic acid therapy an ingestible solid pharmaceutically acceptable formulation comprising a therapeutic dose of tranexamic acid and at least one excipient wherein the excipient retards tranexamic acid release in the stomach and substantially releases tranexamic acid in the small intestine thereby reducing the concentration of tranexamic acid in the stomach during therapy.

Claim 26. (Original) The method of claim 25 further reducing adverse gastrointestinal side effects of therapy.

Claim 27. (Original) The method of claim 25, wherein the at least one excipient controls release of tranexamic acid in the stomach.

Claim 28. (Original) The method of claim 25, wherein the at least one excipient retards release of tranexamic acid in the stomach.

Claim 29. (Original) The method of claim 25, wherein the therapeutic dose is in the range of about 375 mg tranexamic acid to about 1 gram tranexamic acid per dose.

Claim 30. (Original) The method of claim 25, wherein the dose is administered three times a day or four times a day.

Claim 31. (Original) The method of claim 30, wherein the dose is at least two solid tablets or one sachet containing granules.

Claim 32. (Original) A therapeutic method comprising providing tranexamic acid therapy to a patient in need thereof in a pharmaceutically acceptable oral formulation comprising at least one excipient sufficient to result in a decreased stomach concentration of tranexamic acid after oral ingestion thereby decreasing at least one gastrointestinal adverse effect of said therapy.

Claim 33. (Presently presented) The method of claim 32 comprising, decreasing a gastrointestinal adverse effect selected from the group consisting of nausea, vomiting, diarrhea, constipation, cramping bloating, and combinations thereof.

Claim 34. (Original) The method of claim 32 provided to a patient having menorrhagia.

Claim 35. (Original) A method of reducing gastrointestinal adverse side effects comprising administering an effective amount of an extended release pharmaceutical composition comprising tranexamic acid and at least one agent that controls release of tranexamic acid from the composition in the gastrointestinal tract.

Claim 36. (Original) A method of reducing gastrointestinal adverse side effects comprising administering an effective amount of a composition comprising tranexamic acid in an oral administrable formulation selected from the group consisting of extended release, delayed release, and combinations thereof, wherein upon oral administration tranexamic acid is substantially released in the small intestine.